Stockscreener 앱 받기
4.785
3.92%
-0.195
전일 마감가:
$4.98
열려 있는:
$4.85
하루 거래량:
10,129
Relative Volume:
0.20
시가총액:
$86.64M
수익:
-
순이익/손실:
$-9.46M
주가수익비율:
-0.1653
EPS:
-28.9457
순현금흐름:
$-8.70M
1주 성능:
-4.11%
1개월 성능:
-2.94%
6개월 성능:
+46.33%
1년 성능:
-7.27%
1일 변동 폭
$4.725
$4.875
1주일 범위
$4.60
$5.24
52주 변동 폭
$2.66
$7.00
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
Compare ATHE vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.78 | 90.27M | 0 | -9.46M | -8.70M | -28.95 |
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.81 | 70.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.02 | 54.72B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.90 | 38.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
266.35 | 36.23B | 4.29B | 577.22M | 641.34M | 4.2086 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
Weiss Ratings Stock Recommendations & Analyst Ratings 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
ATHE News | ALTERITY THERAPEUTICS-ADR (NASDAQ:ATHE) - ChartMill
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC FilingForm 6-K - Stock Titan
Jones Trading initiates Alterity Therapeutics stock with buy rating - Investing.com
Alteriry Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ATHE) - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Sahm
Insights: Alterity Therapeutics Ltd (ASX:ATHDA) - smallcaps.com.au
ATHEAlterity Therapeutics Ltd ADR Short Interest - Finviz
Alterity Therapeutics (NASDAQ: ATHE) sets vote on 50:1 consolidation and large option, incentive issuances - Stock Titan
Alterity Therapeutics appoints Ann Cunningham to board - Investing.com
Alterity Therapeutics appoints Ann Cunningham to board By Investing.com - Investing.com India
Nerves settle as oil drops - The Cairns Post
Alterity Therapeutics Receives Positive FDA Feedback for ATH434 Phase 3 MSA Program - smallcaps.com.au
ATA Inc. (NASDAQ:AACG) Sees Large Decline in Short Interest - Defense World
Actelis Networks, Inc. (NASDAQ:ASNS) Sees Large Decline in Short Interest - Defense World
Purple Biotech Stock Scheduled to Reverse Split on Monday, March 2nd (NASDAQ:PPBT) - Defense World
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February - Defense World
Ameritas Investment Partners Inc. Raises Stock Holdings in Kratos Defense & Security Solutions, Inc. $KTOS - Defense World
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Upgraded at Zacks Research - Defense World
Compass Minerals International, Inc. (NYSE:CMP) Receives $22.00 Consensus Price Target from Analysts - Defense World
Benjamin Edwards Inc. Acquires 2,629 Shares of iShares Russell 1000 Value ETF $IWD - Defense World
AOT Growth & Innovation ETF (NASDAQ:AOTG) Short Interest Update - Defense World
Allspring Global Investments Holdings LLC Purchases 1,956,470 Shares of Allspring Special Large Value ETF $ASLV - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Insights: Alterity Therapeutics Ltd (ASX:ATH) - smallcaps.com.au
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Finviz
Quantum Biopharma (QNTM) Short Interest & Short Float | Updated May 2026 - MarketBeat
Liminatus Pharma (LIMN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
ATHE SEC FilingsAlterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity Therapeutics announces trading halt - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
- SEC.gov
Cadrenal Therapeutics (CVKD) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Bullfrog AI (BFRG) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Alterity Therapeutics LtdADR (ATHE) News, Articles, Events & Latest Updates - Stocktwits
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology By Investing.com - Investing.com India
Imunon (IMNN) Short Interest & Short Float | Updated May 2026 - MarketBeat
Quince Therapeutics (QNCX) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy - Barchart.com
What is the current Price Target and Forecast for Alterity Therapeutics LimitedSponsored ADR (ATHE) - Zacks Investment Research
Mainz Biomed (MYNZ) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
These stocks are moving in today's pre-market session - ChartMill
Portage Biotech (PRTG) Short Interest & Short Float | Updated Apr 2026 $PRTG - MarketBeat
Which stocks are gapping on Wednesday? - ChartMill
Which stocks are moving before the opening bell on Thursday? - ChartMill
Friday's session: gap up and gap down stocks - ChartMill
알테리티 테라퓨틱스 (ATHE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.47%
자본화:
|
볼륨(24시간):